Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancing cisplatin drug sensitivity through PARP3 inhibition: The influence on PDGF and G-coupled signal pathways in cancer.

Chemico-biological interactions - 1 Aug 2024

Varol Ayşegül, Klauck Sabine M, Dantzer Françoise, Efferth Thomas

Abstract excerpt

Drug resistance poses a significant challenge in cancer treatment despite the clinical efficacy of cisplatin. Identifying and targeting biomarkers open new ways to improve therapeutic outcomes. In this study, comprehensive bioinformatic analyses were employed, including a comparative analysis of multiple datasets, to evaluate overall survival and mutation hotspots in 27 base excision repair (BER) genes of more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Cycle Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Platelet-Derived Growth Factor

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Source

Identifiers

PMID: 38830565
DOI: 10.1016/j.cbi.2024.111094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancing cisplatin drug sensitivity through PARP3 inhibition: The influence on PDGF and G-coupled signal pathways in cancer.PMID 38830565Read ↗

Genome-Wide Mapping of Cisplatin Damaged Gene LociSemantic proximity Read ↗

PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outsSemantic proximity Read ↗

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read ↗

A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistanceSemantic proximity Read ↗

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read ↗

Mapping the Human Kinome in Response to DNA DamageSemantic proximity Read ↗

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-AnalysisSemantic proximity Read ↗

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor ResistanceSemantic proximity Read ↗

Predicting responses to platin chemotherapy agents with biochemically-inspired machine learningSemantic proximity Read ↗

Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)Semantic proximity Read ↗

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read ↗

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.